Overview
- 5 public-safe observations are available for this inspection.
- 5 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
6 Sep 2013
21 CFR 211.22(d)
Procedures not in writing, fully followed
Cited by Nicholas A Violand, Xiaokuang Lai
6 Sep 2013
21 CFR 211.110(a)
Control procedures to monitor and validate performance
Cited by Nicholas A Violand, Xiaokuang Lai
6 Sep 2013
21 CFR 211.113(b)
Procedures for sterile drug products
Cited by Nicholas A Violand, Xiaokuang Lai
6 Sep 2013
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Nicholas A Violand, Xiaokuang Lai
Inspected site
TPTakeda Pharmaceutical Company LimitedYodogawa-Ku, Japan
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.110(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.113(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.165(e) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.22(d) | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 5 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere